Out-of-pocket spending among a cohort of Australians living with gout.

Nathan, N; Nguyen, AD; Stocker, S; Laba, T-L; Baysari, MT; Day, RO

Out-of-pocket spending among a cohort of Australians living with gout.

Nathan, N Nguyen, AD Stocker, S Laba, T-L Baysari, MT Day, RO

Permalink

Publisher:: WILEY
Publication Type:: Journal Article
Citation:: Int J Rheum Dis, 2021, 24, (3), pp. 327-334
Issue Date:: 2021-03

Closed Access

	Filename	Description	Size
	Int J of Rheum Dis - 2020 - Nathan - Out‐of‐pocket spending among a cohort of Australians living with gout.pdf	Published version	675.67 kB		View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Nathan, N
dc.contributor.author	Nguyen, AD
dc.contributor.author	Stocker, S
dc.contributor.author	Laba, T-L
dc.contributor.author	Baysari, MT
dc.contributor.author	Day, RO
dc.date.accessioned	2022-04-20T01:49:12Z
dc.date.available	2020-09-07
dc.date.available	2022-04-20T01:49:12Z
dc.date.issued	2021-03
dc.identifier.citation	Int J Rheum Dis, 2021, 24, (3), pp. 327-334
dc.identifier.issn	1756-1841
dc.identifier.issn	1756-185X
dc.identifier.uri	http://hdl.handle.net/10453/156494
dc.description.abstract	OBJECTIVE: To measure the direct and indirect out-of-pocket (OOP) costs borne by Australians with gout. METHODS: A cross-sectional, Australia-wide, web-based survey was conducted over 12 months between May 2017 and April 2018. Participants were recruited via advertisements in doctors' clinics and healthcare organizations' websites, and social media platforms such as Facebook and Twitter. Survey questions collected information about participants' OOP spending on direct medical and non-medical gout-related healthcare costs. Participant demographics, gout status, healthcare sought, workdays lost to due gout and health-related quality of life were also collected. RESULTS: Seventy-nine patients with gout completed the survey; 70 (89%) were male, and on average were 56 (SD 16) years of age and had gout for 14 (SD 12) years. For this cohort, the median total OOP direct medical cost was AU$200 per year (interquartile range [IQR]: AU$60-AU$570). Sixty (76%) people with gout reported being affected by gout during work; however, only 0.25 (IQR: 0-3) days of work (approximately $60) were lost due to gout in a year. Nine percent (n = 7) of participants experienced cost-related treatment attrition and 33% reported economic hardship (n = 26). Participants who experienced economic hardship or cost-related treatment attrition had higher median total gout-related direct costs than those who did not. CONCLUSION: In Australia, gout has an OOP financial cost and reduces work productivity. The presence of cost-related treatment attrition among people with gout indicates that financial costs may be a significant barrier to seeking treatment for a subset of patients with gout.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	WILEY
dc.relation	http://purl.org/au-research/grants/nhmrc/APP1110230
dc.relation	http://purl.org/au-research/grants/nhmrc/GNT1110230
dc.relation.ispartof	Int J Rheum Dis
dc.relation.isbasedon	10.1111/1756-185X.13979
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1103 Clinical Sciences, 1107 Immunology, 1108 Medical Microbiology
dc.subject.mesh	Australia
dc.subject.mesh	Cost of Illness
dc.subject.mesh	Cross-Sectional Studies
dc.subject.mesh	Female
dc.subject.mesh	Gout
dc.subject.mesh	Health Care Costs
dc.subject.mesh	Health Expenditures
dc.subject.mesh	Humans
dc.subject.mesh	Incidence
dc.subject.mesh	Male
dc.subject.mesh	Middle Aged
dc.subject.mesh	Poverty
dc.subject.mesh	Quality of Life
dc.subject.mesh	Retrospective Studies
dc.subject.mesh	Socioeconomic Factors
dc.subject.mesh	Humans
dc.subject.mesh	Gout
dc.subject.mesh	Incidence
dc.subject.mesh	Retrospective Studies
dc.subject.mesh	Cross-Sectional Studies
dc.subject.mesh	Cost of Illness
dc.subject.mesh	Quality of Life
dc.subject.mesh	Poverty
dc.subject.mesh	Socioeconomic Factors
dc.subject.mesh	Middle Aged
dc.subject.mesh	Health Care Costs
dc.subject.mesh	Health Expenditures
dc.subject.mesh	Australia
dc.subject.mesh	Female
dc.subject.mesh	Male
dc.title	Out-of-pocket spending among a cohort of Australians living with gout.
dc.type	Journal Article
utslib.citation.volume	24
utslib.location.activity	England
utslib.for	1103 Clinical Sciences
utslib.for	1107 Immunology
utslib.for	1108 Medical Microbiology
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Strength - CHERE - Centre for Health Economics Research and Evaluation
utslib.copyright.status	closed_access	*
dc.date.updated	2022-04-20T01:49:10Z
pubs.issue	3
pubs.publication-status	Published
pubs.volume	24
utslib.citation.issue	3

Abstract:

OBJECTIVE: To measure the direct and indirect out-of-pocket (OOP) costs borne by Australians with gout. METHODS: A cross-sectional, Australia-wide, web-based survey was conducted over 12 months between May 2017 and April 2018. Participants were recruited via advertisements in doctors' clinics and healthcare organizations' websites, and social media platforms such as Facebook and Twitter. Survey questions collected information about participants' OOP spending on direct medical and non-medical gout-related healthcare costs. Participant demographics, gout status, healthcare sought, workdays lost to due gout and health-related quality of life were also collected. RESULTS: Seventy-nine patients with gout completed the survey; 70 (89%) were male, and on average were 56 (SD 16) years of age and had gout for 14 (SD 12) years. For this cohort, the median total OOP direct medical cost was AU$200 per year (interquartile range [IQR]: AU$60-AU$570). Sixty (76%) people with gout reported being affected by gout during work; however, only 0.25 (IQR: 0-3) days of work (approximately $60) were lost due to gout in a year. Nine percent (n = 7) of participants experienced cost-related treatment attrition and 33% reported economic hardship (n = 26). Participants who experienced economic hardship or cost-related treatment attrition had higher median total gout-related direct costs than those who did not. CONCLUSION: In Australia, gout has an OOP financial cost and reduces work productivity. The presence of cost-related treatment attrition among people with gout indicates that financial costs may be a significant barrier to seeking treatment for a subset of patients with gout.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/156494